Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Akazawa, S.
Right arrow Articles by Eguchi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Akazawa, S.
Right arrow Articles by Eguchi, K.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 23, Issue 8 1067-1071, Copyright © 2000 by American Diabetes Association

ARTICLES

Efficacy of troglitazone on body fat distribution in type 2 diabetes

S Akazawa, F Sun, M Ito, E Kawasaki and K Eguchi
Unit of Metabolism/Diabetes and Clinical Nutrition, Nagasaki University School of Medicine, Japan. akazawa@net.nagasaki-u.ac.jp

OBJECTIVE: The insulin-sensitizing action of troglitazone may be mediated through the activation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and the promotion of preadipocyte differentiation in adipose tissue on which troglitazone has depot-specific effects. We investigated the relationship between efficacy of the drug and body fat distribution. Changes in body fat distribution were also investigated by long-term administration of the drug. RESEARCH DESIGN AND METHODS: Troglitazone was given at a dose of 400 mg/day to 20 patients with type 2 diabetes whose diet and sulfonylurea therapy produced unsatisfactory glycemic control (HbA(1c) >7.8%) and whose insulin secretory capacity was found to be preserved (postprandial C-peptide >3 ng/ml). HbA(1c) values, serum lipid levels, and body weight were measured monthly Body fat distribution was evaluated in subcutaneous (SC) and visceral fat using a computed tomography scan at umbilical levels before and after troglitazone therapy RESULTS: During the 1-year troglitazone treatment, HbA(1c) was significantly decreased (from 9.2 +/- 0.2 to 7.1 +/- 0.2%, P < 0.01), showing lowest values at 4-6 months, whereas body weight was significantly increased (BMI 24.6 +/- 0.6 to 25.7 +/- 0.6 kg/m2, P < 0.01). Reduction of HbA(1c) (deltaHbA(1c)) from the baseline value during treatment was significantly greater in obese patients (BMI >26 kg/m2) than in nonobese patients (-3.2 +/- 0.4 vs. -2.1 +/- 0.3%, P < 0.05) and was more significant in women than in men (-3.2 +/- 0.2 vs. - 1.4 +/- 0.2%, P < 0.01). The level of deltaHbA(1c) during treatment showed a significant negative correlation with SC fat area (r = -0.742, P < 0.01) but not with visceral fat area. Weight gain during troglitazone treatment resulted in increased accumulation of SC fat without a change in visceral fat area and, consequently. in a significant decrease in the visceral-to-SC fat ratio. CONCLUSIONS: Predominant accumulation of SC fat for the visceral fat tissue was an important predictor of the efficacy of troglitazone therapy in patients with type 2 diabetes. Greater efficacy of troglitazone was observed in women who were characterized by more accumulation of SC adipose tissue than men. Long-term administration of the drug resulted in weight gain with increased accumulation of SC adipose tissue, probably because of the activation of PPAR-gamma in the region.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
O. Gealekman, A. Burkart, M. Chouinard, S. M. Nicoloro, J. Straubhaar, and S. Corvera
Enhanced angiogenesis in obesity and in response to PPAR{gamma} activators through adipocyte VEGF and ANGPTL4 production
Am J Physiol Endocrinol Metab, November 1, 2008; 295(5): E1056 - E1064.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
W. T. Festuccia, S. Oztezcan, M. Laplante, M. Berthiaume, C. Michel, S. Dohgu, R. G. Denis, M. N. Brito, N. A. Brito, D. S. Miller, et al.
Peroxisome Proliferator-Activated Receptor-{gamma}-Mediated Positive Energy Balance in the Rat Is Associated with Reduced Sympathetic Drive to Adipose Tissues and Thyroid Status
Endocrinology, May 1, 2008; 149(5): 2121 - 2130.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Y. Park, A. Y. Chong, E. K. Cochran, D. E. Kleiner, M. J. Haller, D. A. Schatz, and P. Gorden
Type 1 Diabetes Associated with Acquired Generalized Lipodystrophy and Insulin Resistance: The Effect of Long-Term Leptin Therapy
J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 26 - 31.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
S.-K. Kim, K.-Y. Hur, H.-J. Kim, W.-S. Shim, C.-W. Ahn, S.-W. Park, Y.-W. Cho, S.-K. Lim, H.-C. Lee, and B.-S. Cha
The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment
Eur. J. Endocrinol., August 1, 2007; 157(2): 167 - 174.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
M. C. Granberry, J. B. Hawkins, and A. M. Franks
Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure
Am. J. Health Syst. Pharm., May 1, 2007; 64(9): 931 - 936.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
K. Rautio, J.S. Tapanainen, A. Ruokonen, and L.C. Morin-Papunen
Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study
Hum. Reprod., June 1, 2006; 21(6): 1400 - 1407.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. Franckhauser, S. Munoz, I. Elias, T. Ferre, and F. Bosch
Adipose Overexpression of Phosphoenolpyruvate Carboxykinase Leads to High Susceptibility to Diet-Induced Insulin Resistance and Obesity
Diabetes, February 1, 2006; 55(2): 273 - 280.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
J R Porter and T G Barrett
Monogenic syndromes of abnormal glucose homeostasis: clinical review and relevance to the understanding of the pathology of insulin resistance and {beta} cell failure
J. Med. Genet., December 1, 2005; 42(12): 893 - 902.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. K. Wolford, K. A. Yeatts, S. K. Dhanjal, M. H. Black, A. H. Xiang, T. A. Buchanan, and R. M. Watanabe
Sequence Variation in PPARG May Underlie Differential Response to Troglitazone
Diabetes, November 1, 2005; 54(11): 3319 - 3325.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Ortega-Gonzalez, S. Luna, L. Hernandez, G. Crespo, P. Aguayo, G. Arteaga-Troncoso, and A. Parra
Responses of Serum Androgen and Insulin Resistance to Metformin and Pioglitazone in Obese, Insulin-Resistant Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1360 - 1365.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
Y. Miyazaki, E. De Filippis, M. Bajaj, E. Wajcberg, L. Glass, C. Triplitt, E. Cersosimo, L. J Mandarino, and R. A Defronzo
Predictors of improved glycaemic control with rosiglitazone therapy in type 2 diabetic patients: a practical approach for the primary care physician
The British Journal of Diabetes & Vascular Disease, January 1, 2005; 5(1): 28 - 35.
[Abstract] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
V. Sepilian and M. Nagamani
Effects of Rosiglitazone in Obese Women with Polycystic Ovary Syndrome and Severe Insulin Resistance
J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 60 - 65.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
A. M. Sironi, A. Gastaldelli, A. Mari, D. Ciociaro, V. Postano, E. Buzzigoli, S. Ghione, S. Turchi, M. Lombardi, and E. Ferrannini
Visceral Fat in Hypertension: Influence on Insulin Resistance and {beta}-Cell Function
Hypertension, August 1, 2004; 44(2): 127 - 133.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
S. Shadid and M. D. Jensen
Effects of Pioglitazone Versus Diet and Exercise on Metabolic Health and Fat Distribution in Upper Body Obesity
Diabetes Care, November 1, 2003; 26(11): 3148 - 3152.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
T. Mae, H. Kishida, T. Nishiyama, M. Tsukagawa, E. Konishi, M. Kuroda, Y. Mimaki, Y. Sashida, K. Takahashi, T. Kawada, et al.
A Licorice Ethanolic Extract with Peroxisome Proliferator-Activated Receptor-{gamma} Ligand-Binding Activity Affects Diabetes in KK-Ay Mice, Abdominal Obesity in Diet-Induced Obese C57BL Mice and Hypertension in Spontaneously Hypertensive Rats
J. Nutr., November 1, 2003; 133(11): 3369 - 3377.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
P. J. Larsen, P. B. Jensen, R. V. Sorensen, L. K. Larsen, N. Vrang, E. M. Wulff, and K. Wassermann
Differential Influences of Peroxisome Proliferator-Activated Receptors{gamma} and -{alpha} on Food Intake and Energy Homeostasis
Diabetes, September 1, 2003; 52(9): 2249 - 2259.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. P. Berger, A. E. Petro, K. L. Macnaul, L. J. Kelly, B. B. Zhang, K. Richards, A. Elbrecht, B. A. Johnson, G. Zhou, T. W. Doebber, et al.
Distinct Properties and Advantages of a Novel Peroxisome Proliferator-Activated Protein {gamma} Selective Modulator
Mol. Endocrinol., April 1, 2003; 17(4): 662 - 676.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. K. Gan, K. Samaras, C. H. Thompson, E. W. Kraegen, A. Carr, D. A. Cooper, and D. J. Chisholm
Altered Myocellular and Abdominal Fat Partitioning Predict Disturbance in Insulin Action in HIV Protease Inhibitor-Related Lipodystrophy
Diabetes, November 1, 2002; 51(11): 3163 - 3169.
[Abstract] [Full Text] [PDF]

Home page
 PhysiologyHome page
P. Schling and G. Loffler
Cross Talk Between Adipose Tissue Cells: Impact on Pathophysiology
Physiology, June 1, 2002; 17(3): 99 - 104.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
G. J. Etgen, B. A. Oldham, W. T. Johnson, C. L. Broderick, C. R. Montrose, J. T. Brozinick, E. A. Misener, J. S. Bean, W. R. Bensch, D. A. Brooks, et al.
A Tailored Therapy for the Metabolic Syndrome : The Dual Peroxisome Proliferator-Activated Receptor-{alpha}/{gamma} Agonist LY465608 Ameliorates Insulin Resistance and Diabetic Hyperglycemia While Improving Cardiovascular Risk Factors in Preclinical Models
Diabetes, April 1, 2002; 51(4): 1083 - 1087.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. B. Mayerson, R. S. Hundal, S. Dufour, V. Lebon, D. Befroy, G. W. Cline, S. Enocksson, S. E. Inzucchi, G. I. Shulman, and K. F. Petersen
The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes
Diabetes, March 1, 2002; 51(3): 797 - 802.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
H. Yki-Järvinen
Combination Therapies With Insulin in Type 2 Diabetes
Diabetes Care, April 1, 2001; 24(4): 758 - 767.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2000 by the American Diabetes Association.